Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 82

Results For "Head"

1782 News Found

Gautam Solar donates medical equipment to AIIMS Delhi burns ward
News | September 08, 2023

Gautam Solar donates medical equipment to AIIMS Delhi burns ward

The generous donation includes multiple medical equipments


Biocon Biologics completes integration of Viatris Biosimilars’ business in North America
News | September 07, 2023

Biocon Biologics completes integration of Viatris Biosimilars’ business in North America

Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris


Apollo introduces India's first comprehensive Connected Care Services
Healthcare | September 05, 2023

Apollo introduces India's first comprehensive Connected Care Services

This indigenously developed enhanced care technology is designed to continuously monitor and detect early signs of deterioration in a patient's condition


Shilpa Medicare receives UK MHRA approval for mouth-dissolving strips to treat illnesses
News | September 03, 2023

Shilpa Medicare receives UK MHRA approval for mouth-dissolving strips to treat illnesses

This approval has come from the company's finished dosage form manufacturing facility


Loop's health assurance model drives 200% YoY premium surge across 1000 companies
Healthcare | September 02, 2023

Loop's health assurance model drives 200% YoY premium surge across 1000 companies

Health Assurance is a unique healthcare model that combines health insurance with preventive healthcare with a focus on keeping people healthy while providing sick care for them when needed


Sanofi announces changes to its Executive Committee
People | September 01, 2023

Sanofi announces changes to its Executive Committee

Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.


Pfizer and BioNTech receive positive CHMP opinion for Omicron XBB.1.5-adapted COVID-19 vaccine
News | September 01, 2023

Pfizer and BioNTech receive positive CHMP opinion for Omicron XBB.1.5-adapted COVID-19 vaccine

The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older


BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
Clinical Trials | August 29, 2023

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year


Lynparza plus abi/pred approved in Japan for treatment of prostate cancer
Drug Approval | August 25, 2023

Lynparza plus abi/pred approved in Japan for treatment of prostate cancer

First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent